Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Treating depression alongside rheumatoid arthritis pays off. A 24-week randomized study found that patients with RA and depression who received olokizumab plus antidepressant therapy achieved significantly higher ACR50 response rates (84.3%) than those on olokizumab alone (67.3%). Even more striking: patients whose depressive symptoms resolved by week 4 were nearly six times more likely to reach full remission.
When rheumatoid arthritis and depression collide, treating both conditions together may be the winning strategy. A 24-week prospective, randomized study presented at ACR Convergence 2026 enrolled 125 patients with RA and a concurrent depressive disorder across three treatment arms: olokizumab plus depression pharmacotherapy, olokizumab alone, and conventional synthetic DMARDs (csDMARDs) plus depression pharmacotherapy. The results clearly favored the combined approach.
Patients receiving olokizumab alongside psychiatric medications outperformed the other groups on nearly every measure, from ACR20 and ACR50 response rates to Boolean 1.0 remission. Notably, early resolution of depressive symptoms — by just week 4 — emerged as a powerful predictor of long-term remission.
By the Numbers
Why it matters: Depression is common in RA patients and often undertreated. This study suggests that integrating psychiatric care into rheumatology treatment plans isn't just good for mental health — it could meaningfully improve joint disease outcomes too.
